Drug discovery and development – Page 23
-
ArticleDissolving insoluble drugs
How spray drying can help with solubility and bioavailability challenges in drug development
-
ArticlePlatinum metal complexes in medicine
The history of cisplatin, the drug that is still the gold – or should that be platinum? – standard in cancer drugs
-
ArticleBiosensors, wearables and virtual biotech
In a world that is racing ahead with new technologies, has the drug development process distanced itself from the patients it ultimately provides for?
-
ArticleWhy biocatalysis is so on trend
Biocatalysis has come a long way from just beer – there’s an enzyme for nearly everything
-
ArticleThe ever-increasing attraction of biologics
Biologics promise targeted treatments for a range of conditions – if we can overcome the technological challenges
-
FeatureThe antibiotic countdown
Where are the next generation of antibiotics going to come from? Clare Sansom looks at the pipeline
-
ResearchAntimalarial plant's chlorophyll catalyses drug synthesis
New ‘green’ method makes malaria-fighting artemisinin’s synthesis faster and cheaper with industrial production planned for 2021
-
NewsIllegal antibiotic combinations threaten efforts to battle antimicrobial resistance
Unapproved formulations make up two-thirds of combination therapies sold in India
-
ResearchAntibiotic analogue puts researchers on path to ending herbicide drought
Research flags DNA gyrase as a new target for pesticides
-
ResearchSoil search unearths new class of antibiotics
Malacidins have a novel mode of action and can kill MRSA
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessFDA new drug approvals more than doubled in 2017
The FDA approved 46 new drugs last year – the highest number in over two decades – due to factors like streamlined policies at the agency
-
NewsChanging political climate threatens US cannabis research
Trump administration reverses rule protecting states with legalised marijuana
-
BusinessDementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
ResearchSuzuki–Miyaura–hydrogenation targets 3D drugs
Researchers design a new pathway to make sp3 enriched drug molecules
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessSanofi ordered to pull dengue vaccine
Philippines wants French drugmaker to cover immunisation program costs
-
OpinionChanging the reproducibility rulebook
It pays to know when taking shortcuts is acceptable, and which it’s safe to take
-
FeatureStaying one step ahead of the game
Clare Sansom examines the need for agile drug development when tackling emerging viral disease outbreaks
-
BusinessGSK’s shingles vaccine gets thumbs up in North America
Inoculation slated to be a blockbuster